Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
Novartis tosses more US PD-1 submission plans and another anti-CD40 drug indication
Buried in Novartis’ third quarter report were a few key indication drops.
First, Novartis is no longer planning to submit tislelizumab for FDA approval in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.